Results 311 to 320 of about 167,693 (338)

Impact of Drug–Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real‐World Study

open access: yesPigment Cell &Melanoma Research, Volume 38, Issue 4, July 2025.
ABSTRACT The unique pharmacokinetics of BRAF and MEK inhibitors make patients vulnerable to drug–drug interactions (DDIs), which may compromise treatment efficacy in metastatic melanoma. This study evaluates the impact of DDIs on clinical outcomes in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
Silvia Mezi   +14 more
wiley   +1 more source

Breakdown of C3 complement and IgG in peritonitis exudate-pathophysiological aspects and therapeutic approach [PDF]

open access: yes, 1988
Billing, A.   +5 more
core  

Immunosuppressive and Non‐Immunosuppressive Drugs for Heart Xenotransplantation in Humans: Is Europe Ready?

open access: yesXenotransplantation, Volume 32, Issue 4, July/August 2025.
ABSTRACT Xenotransplantation is becoming an emerging field of interest for the treatment of end‐stage heart disease. In fact, the shortage of human heart donors in European countries requires the increasing investigation of alternative strategies such as heart xenotransplantation.
Nicola Pradegan   +6 more
wiley   +1 more source

50 years of methylprednisolone application in spinal cord injury: a bibliometric analysis. [PDF]

open access: yesActa Neurochir (Wien)
Zhou M   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy